COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge오미크론 변이 급증 중 림프증식성 질환 환자의 코로나19Article Published on 2022-06-132022-09-11 Journal: Cancer cell [Category] COVID19(2023년), SARS, 변종, [키워드] COVID-19 in patient lymphoproliferative disease omicron variant [DOI] 10.1016/j.ccell.2022.04.015 PMC 바로가기 [Article Type] Article
Chronic Lymphocytic Leukemia in the SARS-CoV-2 PandemicSARS-CoV-2 유행병의 만성 림프구성 백혈병Review Published on 2022-02-012022-09-12 Journal: Current oncology reports [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] antagonists anti-CD20 anti-SARS-CoV-2 anti-SARS-CoV-2 immune responses antibody BTK BTK inhibitors cancers Case fatality rate caused CFR CFRs chronic chronic lymphocytic leukemia Clinical course CLL CLL patient CLL patients Comorbidity contribute controls COVID-19 COVID-19 incidence COVID-19 vaccine decrease deficiency Efficacy elevated form General population greater healthy Hospitalization immune immune response immune system Immunosuppression IMPROVE incidence Infection leukemia lymphoproliferative disease malignancies malignancy monoclonal antibodies older patients outbreak outcome Oxygen therapy pandemic Patient patients with comorbidity Prevalence recent reduced reported response risk of death SARS-CoV-2 SARS-CoV-2 positivity severe infections significantly significantly higher Spike-specific antibody the disease the median the SARS-CoV-2 therapy Treatment vaccination Vaccine Vaccines [DOI] 10.1007/s11912-022-01198-z PMC 바로가기 [Article Type] Review
Severe infections in patients with lymphoproliferative diseases treated with new targeted drugs: A multicentric real‐world studyarticle Published on 2021-09-232024-09-02 Journal: Cancer Medicine [Category] 대상포진, [키워드] Infectious diseases infectious risk lymphoproliferative disease Prophylaxis targeted drugs [DOI] 10.1002/cam4.4293 PMC 바로가기 [Article Type] article
Case Report: Severe COVID-19 Pneumonia in a Patient With Relapsed/Refractory Hodgkin’s LymphomaOncology Published on 2021-03-182022-10-31 Journal: Frontiers in Oncology [Category] COVID-19, [키워드] acute respiratory distress adverse outcome Allogeneic allogeneic stem cell ARDS autologous brentuximab Cancer Chemotherapy China coronavirus disease Coronavirus disease 2019 COVID-19 diagnosed Donor donor lymphocyte infusion EBV Effect expected global pandemic graft-versus-host-disease GVHD haematological malignancy Hodgkin’s lymphoma Immunosuppression lymphocyte lymphoma lymphoproliferative disease multiorgan failure Patient reported risk Severe COVID-19 pneumonia Stem cell transplantation suffered syndrome therapy treated viral infection [DOI] 10.3389/fonc.2021.601709 PMC 바로가기 [Article Type] Oncology